Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center

Journal of the American Academy of Dermatology

Volumn 76, Issue 1, 2017, Pages 106-113

  Lee, Haur Yueh ^a,b   Fook Chong, Stephanie ^a   Koh, Hong Yi ^a,b   Thirumoorthy, Tharmotharampillai ^a,b   Pang, Shiu Ming ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

cyclosporine; SCORTEN; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; CHARLSON COMORBIDITY INDEX; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEALTH CARE QUALITY; HOSPITAL MORTALITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARDIZED MORTALITY RATIO; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; AGED; BURN UNIT; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BURN UNITS; CYCLOSPORINE; FEMALE; HOSPITAL MORTALITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME;

EID: 85001115516     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.07.048     Document Type: Conference Paper

References (34)

1. 1 Roujeau, J.C., Stern, R.S., Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994), 1272–1285.
2. 2 Roujeau, J.C., Guillaume, J.C., Fabre, J.P., Penso, D., Flechet, M.L., Girre, J.P., Toxic epidermal necrolysis: incidence and drug etiology in France, 1981-1985. Arch Dermatol 126 (1990), 37–42.
3. 3 Rzany, B., Mockenhaupt, M., Baur, S., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 49 (1996), 769–773.
4. 4 Bastuji-Garin, S., Rzany, B., Stern, R.S., Shear, N.H., Naldi, L., Roujeau, J.C., A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 129 (1993), 92–99.
5. 5 Yang, C.W., Cho, Y.T., Chen, K.L., et al. Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 96 (2016), 525–529.
6. 6 Sekula, P., Dunant, A., Mockenhaupt, M., et al. RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133 (2013), 1197–1204.
7. 7 Chung, W.H., Hung, S.I., Hong, H.S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 428, 2004, 486.
8. 8 Nassif, A., Bensussan, A., Boumsell, L., et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 114 (2004), 1209–1215.
9. 9 Chung, W.H., Hung, S.I., Yang, J.Y., et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14 (2008), 1343–1350.
10. 10 Lee, H.Y., Chung, W.H., Toxic epidermal necrolysis: the year in review. Curr Opin Allergy Clin Immunol 13 (2013), 330–336.
11. 11 Kardaun, S.H., Jonkman, M.F., Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 87 (2007), 144–148.
12. 12 Viard, I., Wehrli, P., Bullani, R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998), 490–493.
13. 13 Valeyrie-Allanore, L., Wolkenstein, P., Brochard, L., et al. Open trial of cyclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163 (2010), 847–853.
14. 14 Hunger, R.E., Hunziker, T., Buettiker, U., Braathen, L.R., Yawalkar, N., Rapid resolution of toxic epidermal necrolysis with anti-TNF alpha treatment. J Allergy Clin Immunol 116 (2005), 923–924.
15. 15 Wolkenstein, P., Latarjet, J., Roujeau, J.C., et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352 (1998), 1586–1589.
16. 16 Heng, Y.K., Lee, H.Y., Roujeau, J.C., Epidermal necrolysis: 60 years of errors and advances. Br J Dermatol 173 (2015), 1250–1254.
17. 17 Lee, H.Y., Dunant, A., Sekula, P., et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 167 (2012), 555–562.
18. 18 Bastuji-Garin, S., Fouchard, N., Bertocchi, M., Roujeau, J.C., Revuz, J., Wolkenstein, P., SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115 (2000), 149–153.
19. 19 Lee, H.Y., Lim, Y.L., Thirumoorthy, T., Pang, S.M., The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized center. Br J Dermatol 169 (2013), 1304–1309.
20. 20 Dodiuk-Gad, R., Olteanu, C., Jeschke, M., et al. Treatment of toxic epidermal necrolysis in North America. J Am Acad Dermatol 73 (2015), 876–877.
21. 21 Sassolas, B., Haddad, C., Mockenhaupt, M., et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmaol Ther 88 (2010), 60–68.
22. 22 Kirchhof, M.G., Miliszewski, M.A., Sikora, S., et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 71 (2014), 941–947.
23. 23 Singh, G.K., Chatterjee, M., Verma, R., Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol 79 (2013), 686–692.
24. 24 Guegan, S., Bastuji-Garin, S., Poszepyczynska-Guuigne, E., et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 126 (2006), 272–276.
25. 25 Imahara, S.D., Holmes, J.H., Heimbach, D.M., et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 27 (2006), 270–275.
26. 26 Trent, J.T., Kirsner, R.S., Romanelli, P., Kerdel, F.A., Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 140 (2004), 890–892.
27. 27 Zhu, Q., Ma, L., Luo, S.Q., Huang, H.Y., Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res 33 (2012), e295–e308.
28. 28 Sekula, P., Liss, Y., Dadivodvic, B., et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 32 (2011), 237–245.
29. 29 Hague, J.S., Goulding, J.M., Long, T.M., Gee, B.C., Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN. Br J Dermatol 157 (2007), 1294–1296.
30. 30 Vaishampayuan, S.S., Das, A.L., Verma, R., SCORTEN: does it need modification?. Indian J Dermatol Venereol Leprol 74 (2008), 35–37.
31. 31 Von Wild, T., Stollwerck, P.L., Namdar, T., et al. Are multimorbidities underestimated in scoring systems of Stevens-Johnson syndrome and toxic epidermal necrolysis like in SCORTEN?. Eplasty, 12, 2012, e35.
32. 32 Bachot, N., Revuz, J., Roujeau, J.C., Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139 (2003), 33–36.
33. 33 Kim, K.J., Lee, D.P., Suh, H.S., et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 85 (2005), 497–502.
34. 34 Hung, C.C., Liu, W.C., Kuo, M.C., et al. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 29 (2009), 633–638.